The article you are looking for is not available.
Perhaps you would be interested in our most recent articles.
When properly integrated through appropriate design planning, validation and alignment with regulatory expectations, continuous monitoring can strengthen contamination control strategies and support ...
read more
GLP-1s have generated large amounts of new safety work. Pharmacovigilance systems are struggling to cope with the volume and complexity.
read more
Chromatography has an important role, but relying on it too long may cost of goods, extend timelines, and complicate regulatory submissions.
read more
Use of MPN for resolution of anomalous results assumes a log-linear death curve, which has never been established in a bi-phasic system.
read more
Lypophilization helps stabilize fragile new modalities, including messenger RNA and the advanced formulation vehicles that deliver them.
read more
Many patients abandon ADC therapies due to the associated toxicities. The next major leap requires designing targeted small molecules for conjugation.
read more
On 1 April this year, the Ph. Eur. Chapter 2.6.7, in its thoroughly revised form, came into force. It applies to medicinal products derived from or manufactured using living cells or biological ...
read more
In vitro anti-tubercular activity of the two novel 1,2,4-triazole derivatives demonstrated dose-dependent inhibition of Mycobacterium tuberculosis.
read more
Bulk solids handling is common in pharmaceutical manufacturing, but it remains one of the most misunderstood and underestimated engineering challenges.
read more
GFF treatment led to a significant improvement in FEV1% and FEV1/FVC ratios and resulted in faster, more consistent improvements than TFF.
read more